{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:08:09Z","timestamp":1773763689784,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,4,6]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cure rates for Hodgkin\u2019s lymphoma are excellent, but excess short-term and long-term morbidities from treatment remain a concern. Immunotherapy targeting both tumor antigens and the immunosuppressive tumor microenvironment in children, adolescents, and young adults with Hodgkin\u2019s lymphoma may improve early response rates and eliminate toxic chemotherapy and radiation, thus minimizing toxicity. We conducted a phase II study to evaluate the safety and overall response rate of brentuximab vedotin and rituximab in combination with risk-adapted chemotherapy in children, adolescents, and young adults with newly diagnosed classic Hodgkin\u2019s lymphoma (cHL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a prospective, phase II, non-randomized, risk-assigned study. Patients were treated and evaluated between 2012 and 2020. Eligible patients were aged \u22651\u2009and \u226430 years old with advanced stage, intermediate-risk, and high-risk newly diagnosed cHL. Patients received four or six cycles of brentuximab vedotin (1.2\u2009mg\/kg), doxorubicin (25\u2009mg\/m<jats:sup>2<\/jats:sup>), vinblastine (6\u2009mg\/m<jats:sup>2<\/jats:sup>), dacarbazine (375\u2009mg\/m<jats:sup>2<\/jats:sup>), and rituximab (375\u2009mg\/m<jats:sup>2<\/jats:sup>). Early response was evaluated following two cycles of therapy. Involved field radiotherapy (IFRT) was restricted to high-risk patients with both bulky disease and slow response or those not in complete response at the end of chemoimmunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty patients were enrolled, with a median age of 15\u2009years (4\u201323). There were 18 intermediate-risk and 12 high-risk patients. Toxicities included grade III mucositis (3%), infusion reaction (3%), and peripheral neuropathy (6%). There was a 100% complete response rate on completion of chemoimmunotherapy. Eighteen patients (60%) achieved a rapid early response. Four patients (13%) required IFRT. The 5-year event-free and overall survival rates were 100%, with a median follow-up of 62 months (18\u2013105).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Immunotherapy with brentuximab vedotin, rituximab, and risk-adapted chemotherapy is safe in children, adolescents, and young adults with newly diagnosed cHL. We have demonstrated 100% complete response and 100% event-free and overall survival rates at a median 5-year follow-up, with a significant reduction in use of more toxic chemotherapy and IFRT. A larger cohort is required to confirm these preliminary findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02398240\">NCT02398240<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-004445","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:36:00Z","timestamp":1652873760000},"page":"e004445","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin\u2019s lymphoma: a phase II, non-randomized controlled trial"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02398240","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02398240","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jessica","family":"Hochberg","sequence":"first","affiliation":[{"name":"Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn","family":"Basso","sequence":"additional","affiliation":[{"name":"Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhu","family":"Shi","sequence":"additional","affiliation":[{"name":"Epidemiology and Community Health, New York Medical College, Valhalla, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Klejmont","sequence":"additional","affiliation":[{"name":"Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allyson","family":"Flower","sequence":"additional","affiliation":[{"name":"Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Bortfeld","sequence":"additional","affiliation":[{"name":"Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Harrison","sequence":"additional","affiliation":[{"name":"Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmella","family":"van de Ven","sequence":"additional","affiliation":[{"name":"Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitti","family":"Moorthy","sequence":"additional","affiliation":[{"name":"Radiology, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humayun","family":"Islam","sequence":"additional","affiliation":[{"name":"Pathology, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry","family":"Gerard","sequence":"additional","affiliation":[{"name":"Radiology, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Voss","sequence":"additional","affiliation":[{"name":"Radiology, Boston Children's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-434X","authenticated-orcid":false,"given":"Mitchell S","family":"Cairo","sequence":"additional","affiliation":[{"name":"Pediatrics, New York Medical College, Valhalla, New York, USA"},{"name":"Pathology, New York Medical College, Valhalla, New York, USA"},{"name":"Medicine, New York Medical College, Valhalla, New York, USA"},{"name":"Microbiology & Immunology, New York Medical College, Valhalla, New York, USA"},{"name":"Cell Biology & Anatomy, New York Medical College, Valhalla, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"2025100302275608000_10.5.e004445.1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PPO.0000000000000345","article-title":"Lymphoma in adolescents and young adults: current perspectives","volume":"24","author":"Hochberg","year":"2018","journal-title":"Cancer J"},{"key":"2025100302275608000_10.5.e004445.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30537-0"},{"key":"2025100302275608000_10.5.e004445.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa060185"},{"key":"2025100302275608000_10.5.e004445.4","doi-asserted-by":"publisher","DOI":"10.1667\/RR1903.1"},{"key":"2025100302275608000_10.5.e004445.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949"},{"key":"2025100302275608000_10.5.e004445.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229583"},{"key":"2025100302275608000_10.5.e004445.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-189688"},{"key":"2025100302275608000_10.5.e004445.8","unstructured":"Swerdlow S , Campo E , Harris NL . Classification of tumours of haematopoietic and lymphoid tissues. 4th edn. IARC Press, 2008: 323\u20135."},{"key":"2025100302275608000_10.5.e004445.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1278"},{"key":"2025100302275608000_10.5.e004445.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3629"},{"key":"2025100302275608000_10.5.e004445.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"2025100302275608000_10.5.e004445.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"2025100302275608000_10.5.e004445.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"2025100302275608000_10.5.e004445.14","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"key":"2025100302275608000_10.5.e004445.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.420"},{"key":"2025100302275608000_10.5.e004445.16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11511"},{"key":"2025100302275608000_10.5.e004445.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405456"},{"key":"2025100302275608000_10.5.e004445.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-402792"},{"key":"2025100302275608000_10.5.e004445.19","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"2025100302275608000_10.5.e004445.20","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025100302275608000_10.5.e004445.21","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with Brentuximab Vedotin and Risk-Adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100302275608000_10.5.e004445.22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.199844"},{"key":"2025100302275608000_10.5.e004445.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4606"},{"key":"2025100302275608000_10.5.e004445.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278796"},{"key":"2025100302275608000_10.5.e004445.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.6545"},{"key":"2025100302275608000_10.5.e004445.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.059"},{"key":"2025100302275608000_10.5.e004445.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.5791"},{"key":"2025100302275608000_10.5.e004445.28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2015.11.046","article-title":"Radiation-Related new primary solid cancers in the childhood cancer Survivor study: comparative radiation dose response and modification of treatment effects","volume":"94","author":"Inskip","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100302275608000_10.5.e004445.29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji290"},{"key":"2025100302275608000_10.5.e004445.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8835"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:28:05Z","timestamp":1759483685000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jitc-2021-004445"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004445","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}